The Optic Nerve Injury drugs in development market research report provides comprehensive information on the therapeutics under development for Optic Nerve Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Optic Nerve Injury. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Optic Nerve Injury and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Optic Nerve Injury by ten companies/universities/institutes. The top development phase for Optic Nerve Injury is preclinical with seven drugs in that stage. The Optic Nerve Injury pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Optic Nerve Injury pipeline products market are: NeuroScientific Biopharmaceuticals, ECM Therapeutics and Life Biosciences.
The key targets in the Optic Nerve Injury pipeline products market include Prolow Density Lipoprotein Receptor Related Protein 1 (Alpha 2 Macroglobulin Receptor or Apolipoprotein E Receptor or CD91 or LRP1), High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1), and Krueppel Like Factor 4 (Epithelial Zinc Finger Protein EZF or Gut Enriched Krueppel Like Factor or KLF4).
The key mechanisms of action in the Optic Nerve Injury pipeline product include High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) Agonist with two drugs in Phase II. The Optic Nerve Injury pipeline products include four routes of administration with the top ROA being Intramuscular and six key molecule types in the Optic Nerve Injury pipeline products market including Recombinant Protein, and Small Molecule.
Optic Nerve Injury overview
Optic Nerve Injury or optic neuropathy is a common cause of vision loss occurring as a result of damage to the optic nerve. Optic nerve is a group or bundle of nerve fibers that carry out the communication between the eyes and brain. Trauma can be a common cause or complicated cases of diabetic retinopathy can also cause ONI. Neuroimaging studies are performed to diagnose the condition and patients are presented with blurred or loss of vision, pain, color vision loss. Steroids are first line of therapy followed by surgery and conservative management.
For a complete picture of Optic Nerve Injury’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
